Compare
Compare archived captures
This view highlights text differences between two archived captures. It does not interpret meaning or provide guidance.
Descriptive changes only
This comparison highlights text changes between archived captures. It does not interpret the change or provide medical advice. For up-to-date recommendations, always consult the official source website.
Need to cite this comparison? See /cite.
Earlier capture
Regulating autologous stem cell products prepared at point-of-care: Summary report - Canada.ca
Apr 18, 2025
legacy-hc-2025-04-21
ID 249778
Later capture
Regulating autologous stem cell products prepared at point-of-care: Summary report - Canada.ca
Jan 2, 2026
hc-20260101
ID 428835
updated1 sections changed
1 sections changed0 added0 removed+0 / -1 linesChange ratio: 1%
--- +++ @@ -81,5 +81,4 @@ Dr. Le gave the closing remarks from a stakeholder viewpoint. After acknowledging the challenges faced by Health Canada and stakeholders in managing benefits and risks he stated that the ATP Pathway is a potential option for regulating and thus giving patients access to these products. Liz Anne Gillham-Eisen, Director of the Office of Policy and International Collaboration within the Biologic and Radiopharmaceutical Drugs Directorate, gave the closing remarks from Health Canada. She thanked participants for an interesting and productive discussion, and praised the insight given on the regulation of ACTPs. She concluded by reminding participants of Health Canada's role in regulating health products in Canada, including biologic drugs such as blood and cells, and the department's commitment to enabling access for Canadians to safe and effective products. Insights gleaned from this workshop will be considered in the next steps for point-of-care manufactured ACTPs, including the development of an ATP pathway if appropriate. Page details-Date modified: 2022-02-08